More specifically, Hartkopf et al. [45] designed a recombinant strain of MeV that carried a fusion cytosine deaminase (CD) protein, which enhanced the chemosensitivity of ovarian cancer cells in 5-fluoroucacil (5-FU) and used it in vitro and in vivo investigations. The gene discussed is CTLA4; the disease is ovarian carcinoma.